NCT00557401 - An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD | Biotech Hunter

Enrollment

156

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Gastroesophageal Reflux

Interventions

DRUG

XP19986 SR3, 20 mg QD

XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.

DRUG

XP19986 SR3, 40 mg QD

XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.

DRUG

XP19986 SR3, 60 mg QD

XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.

DRUG

XP19986 SR3, 30 mg BID

XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.

DRUG

Placebo

Placebo tablet taken orally for approximately 32 days with titration and taper periods.

Trial Locations (1)

MDS Pharma Services, Irvine

All Listed Sponsors

lead

XenoPort, Inc.

INDUSTRY